Cybin's bought deal financing has been upsized to CAD$30 million.
Psychedelics
Entheon Biomedical Partners with Divergence Neuro Technologies Inc. for Predictive Biomarker Platform Development
Entheon announces a new partnership to advance its psychedelic drug R&D.
Cybin Announces CDN$20 Million Bought Deal Offering
Cybin Corp announces a CAD$20 million financing at a unit price of CAD$2.25.
Psychedelic Schools for ‘Shamans’ Are Popping Up Like Mushrooms
Even before Oregon and Washington, D.C., decriminalized medical psilocybin, the active ingredient in “magic mushrooms,” in November, a market was emerging for schools that teach mental and medical health professionals how to use psychedelics in their treatment.
The public’s perception of the harms of magic mushrooms is in line with science — but not with the law
New research suggests that the public’s perception of the potential harms of magic mushrooms is not in line with drug laws.
What Will The Psychedelics Space Look Like In 2021? Experts Weigh In
In 2020, psychedelics took the world by storm. Over two dozen companies in the sector became publicly listed.
Peter Thiel-backed psychedelics start-up targets schizophrenia ahead of IPO
LONDON — ATAI Life Science, a Peter Thiel-backed start-up, has taken a majority stake in Recognify, a company that is developing drugs to help treat schizophrenia.
Local Massachusetts Lawmakers Unanimously Approve Psychedelics Decriminalization Measure
Local Massachusetts lawmakers on Thursday unanimously approved a resolution to decriminalize a wide range of psychedelics—the latest in a national movement to reform laws on entheogenic plants and fungi.
Mydecine Innovations Group Announces C$10 Million Bought Deal Offering of Units
Mydecine announces a bought-deal financing with units priced at CAD$0.50.
MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience
MindMed's new Chief Development Officer has over a decade of experience leading drug development programs.
Mydecine Innovations Group Upsizes Previously Announced Bought Deal
Mydecine's bought-deal financing is upsized by 50% to CAD $15 million.
Entheon Biomedical Corp. Announces Acquisition of HaluGen Life Sciences Inc.
Entheon acquires a genetic screening company to identify genetic markers that affect reactions to hallucinogenic drugs.
Researchers believe 'magic' mushrooms have the potential to curb obesity
Researchers have started to explore the potential for psilocybin, the psychedelic drug found in "magic" mushrooms, to treat obesity.
UFC looks into Johns Hopkins study on psychedelic drugs as potential therapy for fighters
The UFC is looking to get involved with research into psychedelic drugs as a therapy for fighters' brain health.
MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience
NEW YORK, Jan. 14, 2021 /PRNewswire/ -- MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company today announced the addition of Robert Barrow, an accomplished pharmaceutical executive, as Chief Development Officer.